No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study

Aims: It is debated whether the NRAS-mutant melanoma is more aggressive than NRAS wildtype. It is equally controversial whether NRAS-mutant metastatic melanoma (MM) is more responsive to checkpoint inhibitor immunotherapy (CII). 331 patients treated with CII as first-line were retrospectively recrui...

Full description

Bibliographic Details
Main Authors: Michele Guida, Nicola Bartolomeo, Pietro Quaglino, Gabriele Madonna, Jacopo Pigozzo, Anna M. Di Giacomo, Alessandro M. Minisini, Marco Tucci, Francesco Spagnolo, Marcella Occelli, Laura Ridolfi, Paola Queirolo, Ivana De Risi, Davide Quaresmini, Elisabetta Gambale, Vanna Chiaron Sileni, Paolo A. Ascierto, Lucia Stigliano, Sabino Strippoli, on behalf of the Italian Melanoma Intergroup (IMI) Study
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
melanoma
NRAS mutation
immunotherapy
checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/13/3/475

Internet

https://www.mdpi.com/2072-6694/13/3/475

Similar Items